3 results match your criteria: "Department of Pharmaceutical Sciences University of Basel Basel Switzerland.[Affiliation]"
Initiation of oral hepatitis C virus treatment: Which barriers are pertinent for ambulatory individuals with a history of illicit substance use? A qualitative interview study.
Health Sci Rep
January 2024
Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences University of Basel Basel Switzerland.
Background And Aims: The World Health Organization has set a goal to eradicate hepatitis C virus (HCV) by the year 2030. Nonadherence to HCV treatment has substantial economic implications due to high treatment costs, among others. Barriers to start HCV treatment may be critical.
View Article and Find Full Text PDFExploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners.
Res Pract Thromb Haemost
July 2022
Experimental Haemostasis Group, Department for BioMedical Research DBMR University of Bern Bern Switzerland.
Article Synopsis
- - The study focuses on the FXIII-B subunit, known for stabilizing FXIII-A, and investigates the unclear function of excess free FXIII-B in plasma, particularly its interactions with complement factors.
- - Researchers tested whether FXIII-B could act as a cofactor for complement degradation and used various assays to explore its binding partners, finding no significant interaction with complement components.
- - While FXIII-B didn’t show regulatory activity in the complement system, α-macroglobulin (α2MG) was identified as a potential binding partner, necessitating further investigations to understand this relationship.
Posaconazole therapy may lead to increased serum estradiol levels and development of gynecomastia. Early detection by endocrine hormone measurements may help preventing gynecomastia.
View Article and Find Full Text PDF